Alzamend Neuro™ Secures New Licenses from USF to Treat Alzheimer’s Disease

Salt Lake City, UT, Oct. 29, 2018 (GLOBE NEWSWIRE) — Alzamend Neuro™, Inc. (Alzamend™ or the “Company”) announced today that it secured two new licenses from the University of South Florida (“USF”) that, together, comprise the basis for a therapy targeted to treat agitation in those who are diagnosed with Alzheimer’s disease (AD). The therapy,…

Details

“Stated simply, we formulate the goop, we buy all the raw materials to mix the goop” ….. Fine, here’s your warning letter.

Every ‘small company’ likes to proclaim it’s uniqueness and the astute one’s do it simply – providing a direct yet compelling message on their website.  One such company in the SE USA includes an interview with their SVP, Contract Sales: Human & Animal Health: [#1] Q: What do you do? A: We manufacture over-the-counter drug products,…

Details

AxoGen, Inc. Receives David J. Gury Company of the Year Award from BioFlorida

Award recognizes company’s contribution to Florida’s life sciences industry ALACHUA, Fla., Oct. 18, 2017 (GLOBE NEWSWIRE) — AxoGen, Inc. (NASDAQ:AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, has received the BioFlorida David J. Gury Company of the Year Award. The award, presented this week at the 20th anniversary…

Details